Mesoblast And Mallinckrodt Enter Into Agreement
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- MD Anderson and NIH Fund Trial Using Mesoblast Technologies
- First Quarter Results On Form 6K
- Successful Interim Futility Analysis In P3 Trial for GVHD
- MSB Japan Strategy Highlighted At Business Council Meeting
- Mesoblast Phase 2 Diabetic Kidney Disease Results Published
Later from Mesoblast
- Mesoblast Director Recognized For Cardiovascular Leadership
- Published Results Show MSB Cells Effective In RA Model
- Positive Nine Month RA Results For Mesoblast Cell Therapy
- FDA Grants Mesoblast Fast Track Designation For GVHD
- Durable Three Year Outcomes in Disc Disease
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast